CRISPR Therapeutics AG (LON:0VRQ)

Market Cap	3.25B
Revenue (ttm)	29.81M
Net Income (ttm)	-292.55M
Shares Out	n/a
EPS (ttm)	-3.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,825
Average Volume	9,565
Open	51.23
Previous Close	50.72
Day's Range	47.46 - 51.41
52-Week Range	31.29 - 72.28
Beta	n/a
RSI	56.66
Earnings Date	Feb 21, 2025

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 393
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0VRQ

Financial Performance

In 2024, CRISPR Therapeutics AG's revenue was $37.31 million, a decrease of -89.95% compared to the previous year's $371.21 million. Losses were -$366.25 million, 138.4% more than in 2023.

Financial numbers in USD